Gordon Carl L
Director | Director, 10% Owner
12 companies
Insider Signal Score
74
StrongTrades Analyzed
34
12M Win Rate
82.4%
Avg 3M Return
+12.3%
Avg 12M Return
+47.7%
Gordon Carl L is a Director at NTLA, with reported holdings spanning 12 companies. Recent filings cover 42 purchases and 23 sales. Those positions are worth an estimated $198.3M at current prices.
Our model assigns Gordon Carl L a strong insider score of 74/100, based on 34 past trades. Over a 12-month horizon, 82.4% of those trades were profitable, with an average 12-month return of +47.7%.
Gordon Carl L's largest disclosed position is in MBX as Director, 10% Owner, worth about $49.4M. Net of sales, the recent Form 4 record there shows accumulation of 940,672 shares.
Holdings by Company
NTLAMay 11, 2016
Current Shares2.41M
Value$28.99M
Net Activity+250.0K
Bought: 250.0KSold: 0
ORICMar 30, 2021
Current Shares2.21M
Value$30.38M
Net Activity-271,896
Bought: 281.3KSold: 553.1K
TERNJul 16, 2024
Current Shares1.97M
Est. Value$19.68M
Net Activity+4.25M
Bought: 4.30MSold: 56.2K
AVBPJan 30, 2024
Current Shares1.29M
Value$40.54M
Net Activity+444.4K
Bought: 444.4KSold: 0
RNACJun 27, 2016
Current Shares1.28M
Value$10.99M
Net Activity+550.0K
Bought: 550.0KSold: 0
KROSNov 21, 2025
Current Shares759.2K
Value$8.08M
Net Activity+125.2K
Bought: 375.2KSold: 250.0K
MBXFeb 18, 2025
Current Shares747.9K
Value$49.37M
Net Activity+940.7K
Bought: 940.7KSold: 0
ALECFeb 11, 2019
Current Shares405.9K
Value$848.4K
Net Activity+411.7K
Bought: 411.7KSold: 0
SCTXJul 27, 2026
Current Shares348.8K
Value$8.18M
Net Activity+1.00M
Bought: 1.00MSold: 0
XFORNov 20, 2017
Current Shares271.8K
Value$1.16M
Net Activity+500.0K
Bought: 500.0KSold: 0
ACETJun 5, 2024
Current Shares11.8K
Value$97.1K
Net Activity+4.00M
Bought: 4.00MSold: 0
CMPXApr 9, 2025
Current Shares0
Value-
Net Activity+3.96M
Bought: 7.53MSold: 3.57M
Transaction History
Showing 10 filings
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | SCTX Scribe Therapeutics Inc. | Director | Buy | 1,000,000 | $15.00 | $15,000,000.00 | +286.7% | - | - | |
| Apr 9, 2025 | CMPX Compass Therapeutics, Inc. | Director, 10% Owner | Sell | 3,571,428 | $1.59 | $5,678,570.52 | -100% | +51.4% | +211.4% | |
| Feb 18, 2025 | MBX Mbx Biosciences, Inc. | Director, 10% Owner | Buy | 190,672 | $10.60 | $2,020,755.60 | +1.9% | +11.5% | +269.8% | |
| Sep 16, 2024 | MBX Mbx Biosciences, Inc. | Director, 10% Owner | Buy | 750,000 | $16.00 | $12,000,000.00 | +24.5% | -11.6% | -55.0% | |
| Aug 13, 2024 | KROS Keros Therapeutics, Inc. | Director | Sell | 250,000 | $44.01 | $11,002,500.00 | -19.7% | +52.7% | -68.7% | |
| Jul 16, 2024 | TERN Terns Pharmaceuticals, Inc. | Director, 10% Owner | Sell | 56,164 | $10.00 | $561,640.00 | -0.4% | -21.4% | -45.7% | |
| Jan 30, 2024 | AVBP Arrivent Biopharma, Inc. | Director, 10% Owner | Buy | 444,444 | $18.00 | $7,999,992.00 | +17.2% | -25.7% | +31.9% | |
| Jan 25, 2024 | ACET Adicet Bio, Inc. | Director, 10% Owner | Buy | 3,125,000 | $2.40 | $7,500,000.00 | +47.0% | -24.1% | -62.7% | |
| Jun 27, 2023 | ACET Adicet Bio, Inc. | Director, 10% Owner | Buy | 875,000 | $2.09 | $1,828,750.00 | +12.1% | -34.3% | -37.1% | |
| Dec 23, 2022 | TERN Terns Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 137,931 | $7.25 | $999,999.75 | +2.9% | +10.3% | -20.5% |
Page 1Next →